Skip to main content
SpringerLink
Log in

Antirheumatika und Antiphlogistika

  • Chapter
Arzneiverordnungs-Report 2007

  • 559 Accesses

Auszug

Bei den Verordnungen im Gebiet der Antirheumatika und Antiphlogistika dominieren auch 2006 mit klarem Abstand die nichtsteroidalen Antiphlogistika. Unter diesen ist weiterhin Diclofenac die am häufigsten verordnete Substanz. Nach der Marktrücknahme von zwei selektiven Cyclooxygenase-2-Hemmern (Rofecoxib, Valdecoxib) sind die Verordnungen der verbliebenen Vertreter (Celecoxib, Etoricoxib) gegenüber dem Vorjahr angestiegen. Insgesamt machen die COX-2-Hemmstoffe aber nur noch 6% der verordneten Antiphlogistika aus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): „Aus der UAW-Datenbank“: Kardiovaskuläre Nebenwirkungen sind ein Klasseneffekt aller Coxibe: Konsequenzen für ihre künftige Verordnung. Dtsch Ärztebl 101, A 3365.

    Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528.

    Article  PubMed  CAS  Google Scholar 

  • Brater DC, Harris C, Redfern JS, Gertz BJ (2001): Renal effects of COX-2 selective inhibitors. Am J Nephrol 21: 1–15.

    Article  PubMed  CAS  Google Scholar 

  • Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al (2005): Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102.

    Article  PubMed  CAS  Google Scholar 

  • Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D et al (2001): Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53: 343–353.

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781.

    Article  PubMed  CAS  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110.

    Article  PubMed  CAS  Google Scholar 

  • Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 869.

    Article  PubMed  Google Scholar 

  • Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421.

    Article  PubMed  CAS  Google Scholar 

  • Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29: 1581–1582.

    PubMed  Google Scholar 

  • Deutsche Gesellschaft für Rheumatologie (2002): Überarbeitete Empfehlungen zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich rheumatischen Erkrankungen (Stand Juli 2002). Im Internet unter: www.rheumanet.org/Uploads/dgrhcontent/ml/k6/doc/TNF-Update_Endfassung_12-9-021.pdf

    Google Scholar 

  • DeWitt DL (1999): Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55: 625–631.

    Google Scholar 

  • Dreser H (1899): Pharmakologisches über Aspirin (Acetylsalicylsaüre). Pflügers Arch 76: 306–318.

    Article  CAS  Google Scholar 

  • Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet354: 2106–2111.

    Article  PubMed  CAS  Google Scholar 

  • Eras J, Perazella MA (2001): NSAIDs and the kidney revistied: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 321: 181–190.

    Article  PubMed  CAS  Google Scholar 

  • European Medicines Agency (2005): Public Statement. European Medicines Agency announces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: www.emea.eu.int/htms/hotpress/d6275705.htm

    Google Scholar 

  • European Medicines Agency (2007): Press release. European Medicines Agency recommends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdf

    Google Scholar 

  • FDA Alert for Healthcare Professionals (2005): Valdecoxib (marketed as Bextra). Publiziert am 7. April 2005 unter: www.fda.gov/bbs/topics/news/ 2005/ NEW01171.html

    Google Scholar 

  • FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: www.fda.gov/bbs/topics/news/2004/new01148.html

    Google Scholar 

  • Food and Drug Administration (2004): FDA Public Health Advisory: Safety of Vioxx. Publiziert am 30. September 2004 unter: www.fda.gov/cder/drug/info-page/vioxx/PHA_vioxx.htm

    Google Scholar 

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740.

    PubMed  CAS  Google Scholar 

  • Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005): Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 365: 475–481.

    PubMed  CAS  Google Scholar 

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257–262.

    PubMed  CAS  Google Scholar 

  • Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM (1998): Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Brit J Pharmacol 123: 927–935.

    Article  CAS  Google Scholar 

  • Hawkey CJ (1999): COX-2 inhibitors. Lancet 353: 307–314.

    Article  PubMed  CAS  Google Scholar 

  • Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al (2000): Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 43: 370–377.

    Article  PubMed  CAS  Google Scholar 

  • Jüni P, Rutjes AWS, Dieppe PA (2002): Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Brit Med J 324: 1287–1288.

    Article  PubMed  Google Scholar 

  • Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (2005): Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157–164.

    PubMed  CAS  Google Scholar 

  • Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776–783.

    Article  PubMed  CAS  Google Scholar 

  • Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD et al (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323: 1075–1052.

    Article  Google Scholar 

  • Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282: 1929–1933.

    Article  PubMed  CAS  Google Scholar 

  • Lin J, Zhang W, Jones A, Doherty M (2004): Efficacy of topical non-steroidal antiinflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. Brit med J 329: 324–326.

    Article  PubMed  CAS  Google Scholar 

  • Manger B, Michels H, Nüsslein HG, Schneider M, Sieper J und die Kommission Pharmakotherapie der DGRh (2007): Neufassung der Empfehlungen der Kommission Pharmakotherapie der DGRh. Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 2007 Jan 12 [Epub ahead of print].

    Google Scholar 

  • Meyer R (2005): Pfizer nimmt Bextra vom Markt. Dtsch Ärztebl 102: A 1023.

    Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693–11697.

    Article  PubMed  CAS  Google Scholar 

  • Mukherjee D, Nissen SE, Topol EJ (2001): Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959.

    Article  PubMed  CAS  Google Scholar 

  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005): Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091.

    Article  PubMed  CAS  Google Scholar 

  • Peskar BM, Maricic N, Gretzera B, Schuligoi B, Schmassmann A (2001): Role of cyclooxygenase-2 in gastric mucosal defense. Life Sci 69: 2993–3003.

    Article  PubMed  CAS  Google Scholar 

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759–766.

    Article  PubMed  CAS  Google Scholar 

  • Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group (2004): Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674.

    Article  PubMed  CAS  Google Scholar 

  • Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000): Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284: 1247–1255.

    Article  PubMed  CAS  Google Scholar 

  • Smolen JS, Kalden JR, Scott DJ, Rozman B, Kvien TK, Larsen A et al. for the European Leflunomide Study Group (1999): Efficacy and safety of lef lunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a doubleblind, randomised, multicentre trial. Lancet 353: 259–266.

    Article  PubMed  CAS  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080.

    Article  PubMed  CAS  Google Scholar 

  • Solomon DH, Schneeweiss S, Glynn RJ, Kiota Y, Levin R, Mogun H, Avorn J (2004): Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073.

    Article  PubMed  CAS  Google Scholar 

  • Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235.

    PubMed  CAS  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Böger, R.H., Schmidt, G. (2008). Antirheumatika und Antiphlogistika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation